Profectus, Vyriad deal

Profectus and Vyriad partnered to develop oncolytic vesiculovirus vaccines to treat advanced cancer. The companies will use Vyriad’s recombinant vesicular stomatitis virus (rVSV)-derived oncolytic vi...